FindMyRecallSubscribe
Class II: temporary or reversible health riskTerminated

Central Admixture Pharmacy Services fentaNYL 2 mcg/mL and bupivacaine 0 Recall

fentaNYL 2 mcg/mL and bupivacaine 0

Central Admixture Pharmacy Services Inc · San Diego, CA

Risk level
Class II
Reported by FDA
Aug 9, 2023
Recall ID
D-1070-2023
Check your lot numberHow we source this data

Summary

Central Admixture Pharmacy Services recalled fentaNYL 2 mcg/mL and bupivacaine 0 starting Jul 17, 2023. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-1070-2023 on Aug 9, 2023. Reason: Lack of assurance of sterility: Lack of validation data for sanitization cycles. Status: Terminated.

Why it was recalled

Lack of assurance of sterility: Lack of validation data for sanitization cycles

Product description

fentaNYL 2 mcg/mL and bupivacaine 0.125% PF in 0.9% sodium chloride, Total Volume = 100 mL, Total FentaNYL 200 mcg/100 mL, 100 mL bag, Rx only, CAPS, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-2082-1

Lot numbers, UPCs & expiration codes

Lot: 17-274485, Exp. 9/19/2023; 17-270783, Exp. 7/19/2023; 17-270882, Exp. 7/20/2023; 17-271430, Exp. 7/30/2023; 17-271509, Exp. 7/31/2023; 17-272224, 17-272238, Exp. 8/13/2023; 17-272704, Exp. 8/21/2023; 17-273147, Exp. 8/29/2023.

Where it was sold

Nationwide in the USA

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-1070-2023
Classification
Class II
Status
Terminated
Recall initiated
Jul 17, 2023
FDA report date
Aug 9, 2023
Quantity
1,114 bags
Recall type
Voluntary: Firm initiated
Recalling firm
Central Admixture Pharmacy Services Inc

Original FDA data

Every field from FDA enforcement report D-1070-2023, exactly as published.

Show all FDA fields
City
San Diego
State
CA
Status
Terminated
Country
United States
Event ID
92752
Address
7935 Dunbrook Rd Ste C
Code information
Lot: 17-274485, Exp. 9/19/2023; 17-270783, Exp. 7/19/2023; 17-270882, Exp. 7/20/2023; 17-271430, Exp. 7/30/2023; 17-271509, Exp. 7/31/2023; 17-272224, 17-272238, Exp. 8/13/2023; 17-272704, Exp. 8/21/2023; 17-273147, Exp. 8/29/2023.
Postal code
92126-6322
Report date
Aug 9, 2023
Product type
Drugs
Recall number
D-1070-2023
Classification
Class II
Recalling firm
Central Admixture Pharmacy Services Inc
Product quantity
1,114 bags
Termination date
Mar 21, 2025
Reason for recall
Lack of assurance of sterility: Lack of validation data for sanitization cycles
Voluntary / mandated
Voluntary: Firm initiated
Product description
fentaNYL 2 mcg/mL and bupivacaine 0.125% PF in 0.9% sodium chloride, Total Volume = 100 mL, Total FentaNYL 200 mcg/100 mL, 100 mL bag, Rx only, CAPS, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-2082-1
Distribution pattern
Nationwide in the USA
Recall initiation date
Jul 17, 2023
Initial firm notification
Letter
Center classification date
Aug 3, 2023

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-1070-2023, published Aug 9, 2023. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls